NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer----Tem - Genesis Health System

Rectal Cancer: NRG-GI002 ----Temporarily Closed

NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer----Temporarily Closed

Objective

NRG-GI002 is an ongoing clinical trial that is studying different treatments for rectal cancer.  The treatments being studied change frequently.

This study is temporarily NOT adding new participants while a new treatment group is being added to the trial. 

This randomized phase II trial studies how well veliparib or pembrolizumab work with combination chemotherapy and radiation therapy in treating patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as modified (m)FOLFOX6 regimen, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving veliparib or pembrolizumab with combination chemotherapy and radiation therapy may kill more tumor cells, make the tumor smaller, and reduce the amount of normal tissue that needs to be removed.

For more information please visit the National Cancer Institute.

LOCATIONS:

1. Genesis Cancer Care Institute

1401 W. Central Park Ave.

Davenport, IA 52804

Phone Number: 563-421-1900

2. Genesis Cancer Clinic-Silvis

801 Illini Dr.

Silvis, IL 61282

Phone Number: 563-421-1900

3. Iowa Cancer Specialists

1750 E. 53rd St.

Davenport, IA 52807

Phone Number: 563-345-4325

Principal Investigator(s)
David Spector, MD, PhD

Clinical Trial Categories

  • Cancer
  • Gastro-Intestinal
Sponsor(s)
NRG Oncology
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Various Locations

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email